Sonoma Biotherapeutics Company
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies aimed at treating autoimmune and inflammatory diseases by restoring immune system balance. The company employs proprietary cell-therapy platform technologies to engineer and deliver targeted Treg approaches designed for durable, disease-modifying treatment. Its services include preclinical development, clinical evaluation of Treg-based therapies, and collaboration frameworks for advancing new modalities in immune-mediated conditions. Sonoma Biotherapeutics engages with partners and stakeholders across research, manufacturing, and clinical operations to bring engineered cell therapies from concept toward clinical proof of concept.
Funding Status:
Private
Employee Number:
101-250
Last Funding Date:
2025-11-03
Headquarters:
South San Francisco,California,United States,North America
Founded Date:
2020-01-01
Total Funding:
365300000
Industry:
Quantum Biology
Super Industry:
Quantum Science Applications
Funding Total Value:
365300000
Last Funding Total Usd:
300000
Last Funding Total Currency:
USD
Last Funding Total Value:
300000
Founders:
Alexander Rudensky,Fred Ramsdell,Jeffrey Bluestone,Qizhi Tang